In a video interview during the 66th American Society of Hematology (ASH) Annual Meeting and Exposition in San Diego, California, Sagar Lonial, MD, FACP, discusses multiple myeloma updates from the ASH annual meeting.
He also discusses the excitement around second-wave chimeric antigen receptor (CAR)-T therapies and bispecifics, and how quadruplet regimens are setting the standard for both transplant-eligible and fit, transplant-ineligible multiple myeloma patients.
